Terms: = Endocrine gland cancer AND SMAD4, JIP, Q13485, 4089, ENSG00000141646, MADH4, DPC4 AND Clinical Outcome
10 results:
1. Comprehensive Analysis of Somatic Mutations in Driver Genes of Resected Pancreatic Ductal Adenocarcinoma Reveals KRAS G12D and Mutant TP53 Combination as an Independent Predictor of clinical outcome.
Shoucair S; Habib JR; Pu N; Kinny-Köster B; van Ooston AF; Javed AA; Lafaro KJ; He J; Wolfgang CL; Yu J
Ann Surg Oncol; 2022 Apr; 29(4):2720-2731. PubMed ID: 34792696
[TBL] [Abstract] [Full Text] [Related]
2. smad4 loss is associated with response to neoadjuvant chemotherapy plus hydroxychloroquine in patients with pancreatic adenocarcinoma.
Fei N; Wen S; Ramanathan R; Hogg ME; Zureikat AH; Lotze MT; Bahary N; Singhi AD; Zeh HJ; Boone BA
Clin Transl Sci; 2021 Sep; 14(5):1822-1829. PubMed ID: 34002944
[TBL] [Abstract] [Full Text] [Related]
3. Pattern of Invasion in Human Pancreatic cancer Organoids Is Associated with Loss of smad4 and clinical outcome.
Huang W; Navarro-Serer B; Jeong YJ; Chianchiano P; Xia L; Luchini C; Veronese N; Dowiak C; Ng T; Trujillo MA; Huang B; Pflüger MJ; Macgregor-Das AM; Lionheart G; Jones D; Fujikura K; Nguyen-Ngoc KV; Neumann NM; Groot VP; Hasanain A; van Oosten AF; Fischer SE; Gallinger S; Singhi AD; Zureikat AH; Brand RE; Gaida MM; Heinrich S; Burkhart RA; He J; Wolfgang CL; Goggins MG; Thompson ED; Roberts NJ; Ewald AJ; Wood LD
Cancer Res; 2020 Jul; 80(13):2804-2817. PubMed ID: 32376602
[TBL] [Abstract] [Full Text] [Related]
4. smad4 and TGFβR2 expression in pancreatic ductal carcinoma.
Văduva IA; Mărgăritescu C; Georgescu CV; Enache AO; Pădureanu R; Săftoiu A; Pirici D
Rom J Morphol Embryol; 2019; 60(3):803-809. PubMed ID: 31912090
[TBL] [Abstract] [Full Text] [Related]
5. Early Loss of Forkhead Transcription Factor, O Subgroup, Member 1 Protein in the Development of Pancreatic Ductal Adenocarcinoma.
Al-Zoughbi W; Schauer S; Pichler M; Hoefler G
Pathobiology; 2018; 85(5-6):342-347. PubMed ID: 30227407
[TBL] [Abstract] [Full Text] [Related]
6. Molecular, morphological and survival analysis of 177 resected pancreatic ductal adenocarcinomas (PDACs): Identification of prognostic subtypes.
Schlitter AM; Segler A; Steiger K; Michalski CW; Jäger C; Konukiewitz B; Pfarr N; Endris V; Bettstetter M; Kong B; Regel I; Kleeff J; Klöppel G; Esposito I
Sci Rep; 2017 Feb; 7():41064. PubMed ID: 28145465
[TBL] [Abstract] [Full Text] [Related]
7. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.
Tang LH; Basturk O; Sue JJ; Klimstra DS
Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015
[TBL] [Abstract] [Full Text] [Related]
8. ChIP-seq defined genome-wide map of TGFβ/smad4 targets: implications with clinical outcome of ovarian cancer.
Kennedy BA; Deatherage DE; Gu F; Tang B; Chan MW; Nephew KP; Huang TH; Jin VX
PLoS One; 2011; 6(7):e22606. PubMed ID: 21799915
[TBL] [Abstract] [Full Text] [Related]
9. Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer.
Garrido-Laguna I; Uson M; Rajeshkumar NV; Tan AC; de Oliveira E; Karikari C; Villaroel MC; Salomon A; Taylor G; Sharma R; Hruban RH; Maitra A; Laheru D; Rubio-Viqueira B; Jimeno A; Hidalgo M
Clin Cancer Res; 2011 Sep; 17(17):5793-800. PubMed ID: 21742805
[TBL] [Abstract] [Full Text] [Related]
10. High nuclear S100A6 (Calcyclin) is significantly associated with poor survival in pancreatic cancer patients.
Vimalachandran D; Greenhalf W; Thompson C; Lüttges J; Prime W; Campbell F; Dodson A; Watson R; Crnogorac-Jurcevic T; Lemoine N; Neoptolemos J; Costello E
Cancer Res; 2005 Apr; 65(8):3218-25. PubMed ID: 15833853
[TBL] [Abstract] [Full Text] [Related]
